Utilization Management Strategies for Appropriate Treatment

EP: 1.Heart Failure Clinical and Economic Burden

EP: 2.The Progressive Nature of Heart Failure

EP: 3.Link Between LVEF, NT-ProBNP and Cardiac Remodeling

EP: 4.Improved Understanding of Heart Failure

EP: 5.Treatment Goals for Patients With Heart Failure

EP: 6.The HFrEF Standard of Care

EP: 7.Heart Failure Management Unmet Needs

Now Viewing

EP: 8.Utilization Management Strategies for Appropriate Treatment

EP: 9.Challenges in the Management of HFpEF

EP: 10.Differences in Standard of Care: HFpEF vs HFrEF

EP: 11.Ensuring Timely and Appropriate Access to Therapy

EP: 12.Differences in Economic Burden: HFpEF and HFrEF

EP: 13.PROVE-HF Trial Overview

EP: 14.PARAGON-HF Trial Overview

EP: 15.Recent Findings from the PARALLAX Study

EP: 16.Promising Findings From the TOPCAT Study

EP: 17.Differences in Leading Treatments for Heart Failure

EP: 18.When to Add an SGLT2 Inhibitor to Treatment Regimen

EP: 19.Heart Failure Sites of Care

EP: 20.How Approved Agents Will Change the Standard of Care

EP: 21.Heart Failure Management During COVID-19

Jaime Murillo, MD: The beauty and challenge at the same time in heart failure is that we have 4, some people count 5, different lines of therapy for heart failure. The reality is that they all work. Where we have an opportunity is in trying to define the groups that benefit most from X therapy.

We have beta-blockers, we have spironolactone and the like, we have all these ACE inhibitors, we have ARBs, we have SGLT2 therapy. Unfortunately, because of the nature of the trials, there is no way for us to tell who benefits from what. That’s the reality. Most people will start therapies with, “What is the affordable medication I can start with?” That person may benefit from a different approach, but we don’t know that yet. In our health plan [at United Health Care], what we have done is that we essentially opened the approach with few exceptions. Then we will very rarely use a step therapy, as we call it, before people have access to medications for heart failure. I suspect that that landscape will evolve as we learn more about which patients benefit the best or better from a specific line of therapy for heart failure.